牛牛AI助理已提取核心訊息
On March 5, 2024, Panbela Therapeutics, Inc. received a notification from The Nasdaq Stock Market LLC indicating that the company's common stock will be delisted due to non-compliance with the minimum stockholders equity requirement of $2.5 million as stipulated in Listing Rule 5550(b)(1). The delisting process will commence with the suspension of trading on Nasdaq at the opening of the market on March 7, 2024, followed by the filing of a Form 25 Notification of Delisting with the SEC after the appeal period has passed. Panbela Therapeutics expects its common stock to be quoted on the OTC Pink Market under the same symbol 'PBLA' during the interim. The company has the option to request a review of the Panel's decision within 15 days or the Nasdaq Listing and Hearing Review Council may opt to review the decision within 45 calendar days. Panbela Therapeutics plans to continue its SEC filings and periodic reports despite the delisting.
On March 5, 2024, Panbela Therapeutics, Inc. received a notification from The Nasdaq Stock Market LLC indicating that the company's common stock will be delisted due to non-compliance with the minimum stockholders equity requirement of $2.5 million as stipulated in Listing Rule 5550(b)(1). The delisting process will commence with the suspension of trading on Nasdaq at the opening of the market on March 7, 2024, followed by the filing of a Form 25 Notification of Delisting with the SEC after the appeal period has passed. Panbela Therapeutics expects its common stock to be quoted on the OTC Pink Market under the same symbol 'PBLA' during the interim. The company has the option to request a review of the Panel's decision within 15 days or the Nasdaq Listing and Hearing Review Council may opt to review the decision within 45 calendar days. Panbela Therapeutics plans to continue its SEC filings and periodic reports despite the delisting.
2024年3月5日，Panbela Therapeutics, Inc.收到納斯達克股票市場有限責任公司的通知，該公司的普通股將因未遵守上市規則5550 (b) (1) 規定的250萬美元的最低股東權益要求而退市。退市程序將從2024年3月7日開盤時暫停納斯達克的交易開始，然後在上訴期結束後向美國證券交易委員會提交25號表格的退市通知。Panbela Therapeutics預計，在此期間，其普通股將在場外粉紅市場上市，股票代碼相同 “PBLA”。該公司可以選擇在15天內要求對該小組的決定進行審查，或者納斯達克上市和聽證會審查委員會可以選擇在45個日曆日內審查該決定。儘管已退市，Panbela Therapeutics仍計劃繼續向美國證券交易委員會提交文件和定期報告。
2024年3月5日，Panbela Therapeutics, Inc.收到納斯達克股票市場有限責任公司的通知，該公司的普通股將因未遵守上市規則5550 (b) (1) 規定的250萬美元的最低股東權益要求而退市。退市程序將從2024年3月7日開盤時暫停納斯達克的交易開始，然後在上訴期結束後向美國證券交易委員會提交25號表格的退市通知。Panbela Therapeutics預計，在此期間，其普通股將在場外粉紅市場上市，股票代碼相同 “PBLA”。該公司可以選擇在15天內要求對該小組的決定進行審查，或者納斯達克上市和聽證會審查委員會可以選擇在45個日曆日內審查該決定。儘管已退市，Panbela Therapeutics仍計劃繼續向美國證券交易委員會提交文件和定期報告。
有用
沒用